Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11061038 | 0.97 | F2 (0.34) | F2PRSS1PRSS2PRSS3KDM4E | |
| SCHEMBL7523328 | 0.94 | F2 (0.35) | F2PRSS1PRSS2PRSS3KDM4E | |
| SCHEMBL7525615 | 0.91 | F2 (0.35) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7529954 | 0.85 | CYP1A2 (0.40) | F2PRSS1PRSS2PRSS3KDM4E | |
| SCHEMBL5555268 | 0.84 | F2 (0.37) | F2PRSS1PRSS2PRSS3KDM4E | |
| SCHEMBL11055437 | 0.83 | KDM4E (0.33) | F2PRSS1PRSS2PRSS3KDM4E | |
| Hydrochloric Acid SCHEMBL11052779 | 0.82 | CYP1A2 (0.38) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL9419232 | 0.79 | CYP1A2 (0.43) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL1613627 | 0.79 | F2 (0.43) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL1035933 | 0.78 | CYP1A2 (0.47) | F2PRSS1PRSS2PRSS3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-6440956-B1 | Bicyclic polyaminoacid metal complexes, their process of preparation and their application in medical imaging | GUERBET (FR) | 2002-08-27 | — | — | US | disclosed |
| EP-0882716-B1 | PYRIDINECARBOXAMIDE DERIVATIVES | NISSHIN PHARMA INC (JP) | 2002-04-10 | — | — | EP | disclosed |
| EP-1186305-A1 | New brominated compounds as contrast media for X-ray mammography | Schering Aktiengesellschaft (DE) | 2002-03-13 | — | — | EP | disclosed |
| US-6187285-B1 | IN PARTICULAR MAGNETIC RESONANCE IMAGING (MRI) FOR MAGNETIC CATIONS. | GUERBET (FR) | 2001-02-13 | — | — | US | disclosed |
| US-6046201-A | Pyridinecarboxamide derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| US-5886158-A | Metal complexes of polyamino oxides, and their utilization in diagnostic imaging | GUERBET S.A. (FR) | 1999-03-23 | — | — | US | disclosed |
| US-4474747-A | BROMO-AND I/DO-BENZENE COMPOUNDS | GUERBET S.A. (FR) | 1984-10-02 | — | — | US | disclosed |